Roman V. Kapustin

Dr. Roman V. Kapustin

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 December 2019 in Archives of Gynecology and Obstetrics
Verified
Journal Article
Closed access
PDF file
RKRoman V. Kapustin
Roman V. Kapustin
ADAnna Olegovna Drobintseva
Anna Olegovna Drobintseva
Elena AlekseenkovaElena Alekseenkova
Elena Alekseenkova
AOA. R. Onopriychuk
A. R. Onopriychuk
OAO. N. Arzhanova
O. N. Arzhanova
IKIgor Kvetnoy
Igor Kvetnoy

1 November 2020 in European Journal of Obstetrics & Gynecology and Reproductive Biology
Verified
Journal Article
Closed access
RKRoman V. Kapustin
Roman V. Kapustin
SCSergey V. Chepanov
Sergey V. Chepanov
VBVladimir N. Babakov
Vladimir N. Babakov
NRNadezhda Y. Rogovskaya
Nadezhda Y. Rogovskaya
EKEkaterina V. Kopteeva
Ekaterina V. Kopteeva
OAOlga N. Arzhanova
Olga N. Arzhanova

1 December 2020 in Gynecological Endocrinology
Verified
Journal Article
Open access
RKRoman V. Kapustin
Roman V. Kapustin
SCSergey Chepanov
Sergey Chepanov
EKEkaterina Kopteeva
Ekaterina Kopteeva
OAOlga Arzhanova
Olga Arzhanova
To evaluate serum concentration of 8-isoprostane, nitrotyrosine (NT), and total antioxidant capacity (TAC) in pregnant women with diabetes mellitus (DM) considering preconception planning and metho...

20 December 2021 in Gynecological Endocrinology
Verified
Journal Article
Open access
RKRoman V. Kapustin
Roman V. Kapustin
EKEkaterina Kopteeva
Ekaterina Kopteeva
EAElena N. Alekseenkova
Elena N. Alekseenkova
TTTatyana G. Tral
Tatyana G. Tral
GTGulrukhsor Kh. Tolibova
Gulrukhsor Kh. Tolibova
OAOlga N. Arzhanova
Olga N. Arzhanova
To evaluate a level of expression of endoglin (Eng), leptin (Lep), placental growth factor (PlGF), and hypoxia-inducible factor-1alpha (HIF-1α) in placenta among women with pre-eclampsia and diabet...

9 March 2022 in The Journal of Maternal-Fetal & Neonatal Medicine
Verified
Journal Article
Closed access
ATAlyona V. Tiselko
Alyona V. Tiselko
RKRoman V. Kapustin
Roman V. Kapustin
YMYuliya P. Milyutina
Yuliya P. Milyutina
NBNatalia V. Borovik
Natalia V. Borovik
EAElena I. Abashova
Elena I. Abashova
MYMaria Yarmolinskaya
Maria Yarmolinskaya
To analyze glucose variability and investigate its role as a predictor for preeclampsia development in pregnant women with type 1 diabetes mellitus (T1DM) with various insulin therapy regimens.A to...

14 April 2020 in Journal of obstetrics and women's diseases
Verified
Journal Article
Open access
PDF file
RKRoman V. Kapustin
Roman V. Kapustin
Elena AlekseenkovaElena Alekseenkova
Elena Alekseenkova
OAOlga N. Arzhanova
Olga N. Arzhanova
APAlina V. Petyaeva
Alina V. Petyaeva
MAMadina G. Atayeva
Madina G. Atayeva
ЮРЮсенко Софья Руслановна
Юсенко Софья Руслановна
Hypothesis/aims of study. Diabetes mellitus (DM) is associated with an increased risk of obstetric complications, including preterm birth (PB). The incidence rate of PB in women with DM is higher than in the general population and amounts to 3040%. Nevertheless, there are still open questions on the structure of PB, pharmacological approaches to its prevention and treatment, as well as the feasibility of prolonging the timing of glucocorticoid therapy to reduce perinatal morbidity and mortality. The objective of this study was to research the features of structure and clinical approaches in the case of PB in women with different types of DM, based on a literature review. Study design, materials and methods. The study was performed using literature search, screening, data extraction, and analysis of publications collected in world databases such as MEDLINE, EMBASE, CNKI, and Cochrane. Results. The rate of PB is the highest in women with pregestational DM: 2130% in type 1 DM and 1940% in type 2 DM. The incidence of PB in gestational DM (710%) is almost equal to the general population level (79%) and depends on the type of diabetes therapy: insulin 16%, diet 7%. Risk factors for PB in women with DM are poor glycaemic control, microvascular complications of DM, hypertension, obesity, infection, age, fetal macrosomia, polyhydramnios, and congenital malformations. Adequate glycemic control from early gestation is an important condition for PB prevention. The structure of PB in patients with pregestational DM changes due to an increase in both spontaneous and induced PB proportions. The most common indications for early delivery in DM are preeclampsia, premature placental abruption, impaired renal function in diabetic nephropathy, severe forms of carbohydrate metabolism disorders, diabetic fetopathy, and fetal distress. The risk of fetal respiratory distress syndrome in newborns of mothers with DM is higher than in the general population. The maturity of the lungs of a newborn may be insufficient, even in the case of term delivery. The use of antenatal corticosteroids is effective prophylaxis of respiratory disorders. However, these corticosteroids can increase the risk of neonatal hypoglycemia. Conclusion. Despite the term weight and height, the newborn of a mother with DM may remain immature, therefore, delivery at term is recommended. The gestational age, until which it is advisable to prescribe corticosteroids for pregnant women with DM, and the mode of delivery in the case of PB, remain a matter of debate.